Jacqueline Michelle Ogier

Jacqueline Michelle Ogier

Auto-generated profile, based on publicly available information

Jacqueline Michelle Ogier

Bruce Lefroy Centre, Murdoch Children’s Research Institute, Parkville, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
JOJacqueline M. Ogier
Jacqueline M. Ogier
BNBryony Nayagam
Bryony Nayagam
PLPaul Lockhart
Paul Lockhart
P38 mitogen-activated protein kinases (P38α and β) and c-Jun N-terminal kinases (JNK1, 2, and 3) are key mediators of the cellular stress response. However, prolonged P38 and JNK signalling is associated with damaging inflammatory responses, reactive oxygen species–induced cell death, and fibrosis in multiple tissues, such as the kidney, liver, central nervous system, and cardiopulmonary systems. These responses are associated with many human diseases, including arthritis, dementia, and multiple organ dysfunctions. Attempts to prevent P38- and JNK-mediated disease using small molecule inhibitors of P38 or JNK have generally been unsuccessful. However, apoptosis signal-regulating kinase 1 (ASK1), an upstream regulator of P38 and JNK, has emerged as an alternative drug target for limiting P38- and JNK-mediated disease. Within this review, we compile the evidence that ASK1 mediates damaging cellular responses via prolonged P38 or JNK activation. We discuss the potential benefits of ASK1 inhibition as a therapeutic and summarise the studies that have tested the effects of ASK1 inhibition in cell and animal disease models, in addition to human clinical trials for a variety of disorders.

3 May 2019 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
JOJacqueline M. Ogier
Jacqueline M. Ogier
RBRachel A. Burt
Rachel A. Burt
HDHannah R. Drury
Hannah R. Drury
RLRebecca Lim
Rebecca Lim
BNBryony Nayagam
Bryony Nayagam
The inner ear is a complex organ containing highly specialised cell types and structures that are critical for sensing sound and movement. In vivo, the inner ear is difficult to study due to the osseous nature of the otic capsule and its encapsulation within an intricate bony labyrinth. As such, mammalian inner ear explants are an invaluable tool for the study and manipulation of the complex intercellular connections, structures, and cell types within this specialised organ. The greatest strength of this technique is that the complete organ of Corti, or peripheral vestibular organs including hair cells, supporting cells and accompanying neurons, is maintained in its in situ form. The greatest weakness of in vitro hair cell preparations is the short time frame in which the explanted tissue remains viable. Yet, cochlear explants have proven to be an excellent experimental model for understanding the fundamental aspects of auditory biology, substantiated by their use for over 40 years. In this protocol, we present a modernised inner ear explant technique that employs organotypic cell culture inserts and serum free media. This approach decreases the likelihood of explant damage by eliminating the need for adhesive substances. Serum free media also restricts excessive cellular outgrowth and inter-experimental variability, both of which are side effects of exogenous serum addition to cell cultures. The protocol described can be applied to culture both cochlear and vestibular explants from various mammals. Example outcomes are demonstrated by immunohistochemistry, hair cell quantification, and electrophysiological recordings to validate the versatility and viability of the protocol.

19 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JOJacqueline M Ogier
Jacqueline M Ogier
MCMarina R Carpinelli
Marina R Carpinelli
BABenedicta D Arhatari
Benedicta D Arhatari
RSR C Andrew Symons
R C Andrew Symons
BKBenjamin T Kile
Benjamin T Kile
RBRachel A Burt
Rachel A Burt
CHARGE syndrome is a rare human disorder caused by mutations in the gene encoding chromodomain helicase DNA binding protein 7 (CHD7). Characteristics of CHARGE are varied and include developmental ear and hearing anomalies. Here we report a novel mouse model of CHD7 dysfunction, termed Looper. The Looper strain harbours a nonsense mutation (c.5690C>A, p.S1897X) within the Chd7 gene. Looper mice exhibit many of the clinical features of the human syndrome, consistent with previously reported CHARGE models, including growth retardation, facial asymmetry, vestibular defects, eye anomalies, hyperactivity, ossicle malformation, hearing loss and vestibular dysfunction. Looper mice display an otosclerosis-like fusion of the stapes footplate to the cochlear oval window and blepharoconjunctivitis but not coloboma. Looper mice are hyperactive and have vestibular dysfunction but do not display motor impairment.

1 July 2015 in The American Journal of Pathology
Verified
Journal Article
Closed access
MCMarina R. Carpinelli
Marina R. Carpinelli
EKElizabeth A. Kruse
Elizabeth A. Kruse
BABenedicta D. Arhatari
Benedicta D. Arhatari
MDMarlyse A. Debrincat
Marlyse A. Debrincat
JOJacqueline M. Ogier
Jacqueline M. Ogier
RBRachel A. Burt
Rachel A. Burt

26 December 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
SMSahar Sadat Mahshid
Sahar Sadat Mahshid
AHAliaa Monir Higazi
Aliaa Monir Higazi
JOJacqueline Michelle Ogier
Jacqueline Michelle Ogier
ADAlain Dabdoub
Alain Dabdoub
Rapid diagnostic testing has become a mainstay of patient care, using easily obtained samples such as blood or urine to facilitate sample analysis at the point‐of‐care. These tests rely on the detection of disease or organ‐specific biomarkers that have been well characterized for a particular disorder. Currently, there is no rapid diagnostic test for hearing loss, which is one of the most prevalent sensory disorders in the world. In this review, potential biomarkers for inner ear‐related disorders, their detection, and quantification in bodily fluids are described. The authors discuss lesion‐specific changes in cell‐free deoxyribonucleic acids (DNAs), micro‐ribonucleic acids (microRNAs), proteins, and metabolites, in addition to recent biosensor advances that may facilitate rapid and precise detection of these molecules. Ultimately, these biomarkers may be used to provide accurate diagnostics regarding the site of damage in the inner ear, providing practical information for individualized therapy and assessment of treatment efficacy in the future.

1 February 2020 in Hearing Research
Verified
Journal Article
Open access
JOJacqueline M. Ogier
Jacqueline M. Ogier
PLPaul Lockhart
Paul Lockhart
RBRachel A. Burt
Rachel A. Burt
Many drugs on the World Health Organization's list of critical medicines are ototoxic, destroying sensory hair cells within the ear. These drugs preserve life, but patients can experience side effects including permanent hearing loss and vestibular dysfunction. Aminoglycoside ototoxicity was first recognised 80 years ago. However, no preventative treatments have been developed. In order to develop such treatments, we must identify the factors driving hair cell death. In vivo, studies of cell death are typically conducted using mouse models. However, a robust model of aminoglycoside ototoxicity does not exist. Previous studies testing aminoglycoside delivery via intraperitoneal or subcutaneous injection have produced variable ototoxic effects in the mouse. As a result, surgical drug delivery to the rodent ear is often used to achieve ototoxicity. However, this technique does not accurately model clinical practice. In the clinic, aminoglycosides are administered to humans intravenously (i.v.). However, repeated i.v. delivery has not been reported in the mouse. This study evaluated whether repeated i.v. administration of amikacin or tobramycin would induce hearing loss. Daily i.v. injections over a two-week period were well tolerated and transient low frequency hearing loss was observed in the aminoglycoside treatment groups. However, the hearing changes observed did not mimic the high frequency patterns of hearing loss observed in humans. Our results indicate that the i.v. delivery of tobramycin or amikacin is not an effective technique for inducing ototoxicity in mice. This result is consistent with previously published reports indicating that the mouse cochlea is resistant to systemically delivered aminoglycoside ototoxicity.